Fig. 3From: Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinationsAntitumor effects of D2C7-IT therapy post-CD4+ and CD8+ T cell depletion in orthotopic glioma models. Treatment schedule, survival curves, and median survival are shown for C57BL/6 J mice bearing intracranial CT-2A-dmEGFRvIII-Luc tumors (a) and VM/Dk mice bearing intracranial SMA560-dmEGFRvIII-Luc tumors (b). The p-values generated from the generalized Wilcoxon test are provided for both tumor modelsBack to article page